Premium
Selective oestrogen receptor modulators: an update
Author(s) -
Papaioannou Spyros,
Purdie David W,
Cochrane Geoffrey W
Publication year - 2003
Publication title -
the obstetrician and gynaecologist
Language(s) - English
Resource type - Journals
eISSN - 1744-4667
pISSN - 1467-2561
DOI - 10.1576/toag.5.4.200.26922
Subject(s) - oestrogen receptor , selective estrogen receptor modulator , receptor , pharmacology , medicine , computational biology , biology , estrogen receptor , breast cancer , cancer
This paper discusses new developments in the area of selective oestrogen receptor modulators and more specifically raloxifene. The most exciting of these developments is the observed reduction in the risk of breast cancer in postmenopausal women on raloxifene therapy. The license of the product has now been extended to cover treatment as well as prevention of osteoporosis. Furthermore, raloxifene appears to have a positive impact on the serum lipid profile and there are continuing trials investigating whether these changes translate to a reduction in cardiovascular morbidity and mortality.